News NetraMark Holdings Inc.

Stocks

AIAI

CA64119M1059

Software

Market Closed - Toronto S.E. Other stock markets 15:51:30 2026-07-07 EDT			5-day change	1st Jan Change
0.8400 ^CAD	+1.20%		+33.33%	-23.64%

06-29	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company	MT
06-29	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	CI

All News

Mentions Relevance

06-29	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company	MT
06-29	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	CI
06-29	NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	AQ
06-09	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026	AQ
05-25	Upcoming Meeting Dates - May 25, 2026	NE
05-20	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting	AQ
05-14	NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
05-14	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum	AQ
05-07	NetraMark Announces Change To Board Of Directors	AQ
05-07	NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026	CI
05-05	NetraMark Holdings Inc. (AIAI) Opens the Market	NE
05-04	NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI	AQ
05-04	NetraMark Holdings Inc. Announces Executive Changes	CI
04-30	NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026	AQ
04-22	NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs	AQ
04-22	NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs	CI
04-20	Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development	AQ
04-20	NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics	CI
04-09	Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes	CI
04-09	Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain	AQ
03-25	NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset	MT
03-25	Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration	CI
03-25	NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset	MT
03-25	NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset	AQ
03-19	NetraMark Holdings Inc Unveils Ai-Discovered Treatment-Responsive Subgroups In A4 Alzheimer?s Trial	CI